Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- CLDR -14.2%, ATU -5.9%, PAY -4.2%, HNI -2%, (HNI lowers Q2 revenue and earnings expectations on slower than anticipated sales in office furniture business), FGP -2%,XTLY -0.6%
Select UK based names showing weakness following UK elections:
- RBS -3.6%, BT -3%, BCS -2.3%, LYG -2.2%, NGG -1.9%, GWPH -1.8%, AZN -1.1%, GSK-0.8%, PUK -0.8%
Other news:
- EYEG -16.1% ( prices 6,666,667 shares of common stock and warrants at $1.50 per share of common stock)
- ENDP -12.9% (FDA requests removal of Opana ER for risks related to abuse; co is reviewing the request and evaluating the full range of potential options )
- MRCC -3.4% (commences an underwritten public offering of shares of its common stock)
- ACGL -2.5% (prices secondary common stock offering of 6.4 mln shares, at $92.50/share)
- CUR -2.4% (thinly traded - files for $100 mln mixed securities shelf offering)
- DEPO -2% (following ENDP FDA news)
- INSY -1.7% (following ENDP FDA news)
- CAA -0.9% (prices Secondary offering by selling shareholders consisting of 42,842,557 shares of common stock at $34.25 per share)
Analyst comments:
- TOO -14.4% (downgraded to Underweight at Morgan Stanley )
- TK -11.2% (downgraded to Underweight at Morgan Stanley )
- SNAP -1.9% (downgraded to Neutral from Buy at Citigroup)
- DPZ -1.4% (downgraded to Neutral from Buy at Longbow)
- TECK -1.3% (downgraded to Neutral from Buy at BofA/Merrill)
- SHPG -1.1% (target lowered to $216 from $239 at Jefferies )